Market closedNon-fractional
GlycoMimetics/GLYC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About GlycoMimetics
GlycoMimetics Inc is a clinical-stage biotechnology company. It is focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the company is developing a pipeline of proprietary glycomimetics that may inhibit disease-related functions of carbohydrates, such as the roles it play in inflammation, cancer, and infection.
Ticker
GLYC
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Rockville, United States
Employees
35
Website
www.glycomimetics.com
GlycoMimetics Metrics
BasicAdvanced
$15M
Market cap
-
P/E ratio
-$0.58
EPS
2.18
Beta
-
Dividend rate
Price and volume
Market cap
$15M
Beta
2.18
Financial strength
Current ratio
6.284
Quick ratio
5.929
Total debt to equity
2.182
Management effectiveness
Return on assets (TTM)
-47.82%
Return on equity (TTM)
-81.84%
Valuation
Price to revenue (TTM)
1,517.419
Price to book
0.53
Price to tangible book (TTM)
0.53
Price to free cash flow (TTM)
-0.448
Growth
Revenue change (TTM)
-86.67%
Earnings per share change (TTM)
-25.51%
3-year revenue growth (CAGR)
-83.48%
3-year earnings per share growth (CAGR)
-21.90%
What the Analysts think about GlycoMimetics
Analyst Ratings
Majority rating from 4 analysts.
GlycoMimetics Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$11M
18.89%
Profit margin
0.00%
NaN%
GlycoMimetics Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.13
-$0.14
-$0.14
-$0.17
-
Expected
-$0.18
-$0.14
-$0.15
-$0.17
-$0.16
Surprise
-29.09%
-2.33%
-8.20%
3.03%
-
GlycoMimetics News
AllArticlesVideos
GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
Business Wire·2 months ago
GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024
Business Wire·2 months ago
GlycoMimetics, Inc. (GLYC) Corporate Update Call Transcript
Seeking Alpha·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for GlycoMimetics stock?
GlycoMimetics (GLYC) has a market cap of $15M as of July 27, 2024.
What is the P/E ratio for GlycoMimetics stock?
The price to earnings (P/E) ratio for GlycoMimetics (GLYC) stock is 0 as of July 27, 2024.
Does GlycoMimetics stock pay dividends?
No, GlycoMimetics (GLYC) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next GlycoMimetics dividend payment date?
GlycoMimetics (GLYC) stock does not pay dividends to its shareholders.
What is the beta indicator for GlycoMimetics?
GlycoMimetics (GLYC) has a beta rating of 2.18. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell GlycoMimetics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.